All data are based on the daily closing price as of April 28, 2025
s
Santen Pharmaceutical
4536.TSE
9.80 USD
-0.01
-0.10%
Overview
Last close
9.80 usd
Market cap
3.35B usd
52 week high
12.72 usd
52 week low
8.89 usd
Target price
14.41 usd
Valuation
P/E
17.9543
Forward P/E
13.4409
Price/Sales
1.6113
Price/Book Value
1.6898
Enterprise Value
2.80B usd
EV/Revenue
1.3291
EV/EBITDA
7.6096
Key financials
Revenue TTM
2.10B usd
Gross Profit TTM
1.20B usd
EBITDA TTM
483.25M usd
Earnings per Share
0.55 usd
Dividend
0.24 usd
Total assets
2.55B usd
Net debt
-498.09M usd
About
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension. In addition, it provides cyclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis; and diquafosol sodium for dry eye treatment. Further, the company develops olodaterol hydrochloride, a ß2 receptor agonist that is in phase 1/2a for the treatment of A dry eye treatment dry eye; sirolimus, an ophthalmic suspension which is in phase 2a for the treatment of 4 Fuchs endothelial corneal dystrophy and meibomian gland dysfunction; epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval for the treatment of allergic conjunctivitis; atropine sulfate, a non-selective muscarinic antagonist that is in phase 2/3 clinical trials for myopia treatment; and AFDX0250BS, an selective muscarinic M2 antagonist which is in phase 2a for the treatment of myopia. Additionally, it offers ursodeoxycholic acid that is in phase 2a of clinical trial for the treatment of presbyopia; and oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase 3 for treatment of ptosis. The company was founded in 1890 and is headquartered in Osaka, Japan.